Chengjiang Zhao

Chengjiang Zhao

Auto-generated profile, based on publicly available information

Chengjiang Zhao

Youjia (Hangzhou) Biomedical Technology Co. Ltd Hangzhou Zhejiang China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2018 in Xenotransplantation
Verified
Journal Article
Closed access
CZChengjiang Zhao
Chengjiang Zhao
DCDavid Cooper
David Cooper
YDYifan Dai
Yifan Dai
HHHidetaka Hara
Hidetaka Hara
ZCZhiming Cai
Zhiming Cai
LMLisha Mou
Lisha Mou

11 May 2019 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
MZMing Zhou
Ming Zhou
YLYing Lu
Ying Lu
CZChengjiang Zhao
Chengjiang Zhao
JZJunfang Zhang
Junfang Zhang
DCDavid Cooper
David Cooper
LMLisha Mou
Lisha Mou

1 June 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JNJie Ning
Jie Ning
CZChengjiang Zhao
Chengjiang Zhao
JCJian-Xiong Chen
Jian-Xiong Chen
DLDuanfang Liao
Duanfang Liao

1 March 2018 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
CZChengjiang Zhao
Chengjiang Zhao
DCDavid Cooper
David Cooper
YDYifan Dai
Yifan Dai
HHHidetaka Hara
Hidetaka Hara
ZCZhiming Cai
Zhiming Cai
LMLisha Mou
Lisha Mou

31 July 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
TTTingke Tang
Tingke Tang
QLQiuying Li
Qiuying Li
CZChenguang Zhang
Chenguang Zhang
YWYongxing Wang
Yongxing Wang
LYLu Yang
Lu Yang
WCWenhao Cui
Wenhao Cui
Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH). This preclinical study evaluates YJH‐012‐D, a N ‐acetylgalactosamine (GalNAc)‐conjugated small interfering RNA (siRNA) targeting hepatic XDH . Functional assays demonstrated that YJH‐012‐D potently suppressed both XDH mRNA and protein expression in primary hepatocytes. In mice, a single subcutaneous dose of 8 mg/kg significantly reduced serum uric acid levels and suppressed hepatic XDH expression for more than 42 days. In cynomolgus monkeys, administration of YJH‐012‐D at 10 mg/kg lowered serum uric acid for up to 180 days, with sustained XDH inhibition observed for 120 days. Pharmacokinetic analysis revealed a high liver‐to‐plasma area under the curve (AUC) ratio (2000–6100) and a hepatic half‐life exceeding 10 days, consistent with prolonged pharmacological activity. Comprehensive toxicity assessments—including clinical biochemistry, histopathology, and RNA sequencing (RNA‐seq)‐based off‐target profiling—identified no significant adverse effects. Collectively, YJH‐012‐D exhibits potent, durable urate‐lowering efficacy and a favorable safety profile, underscoring its potential as a novel therapeutic candidate for HUA.